Mustang Bio Inc (MBIO)
NASDAQ:MBIO
Want to see MBIO full AI Analyst Report?
MBIO Stock Chart & Stats
$1.09
-$0.01(-4.59%)
At close: 4:00 PM EST
$1.09
-$0.01(-4.59%)
Day’s Range― - ―
52-Week Range$0.53 - $7.00
Previous CloseN/A
Volume2.68M
Average Volume (3M)94.14K
Market Cap
$5.77M
Enterprise Value-$11.50M
Total Cash (Recent Filing)$17.27M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta0.90
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding6,732,092
10 Day Avg. Volume88,215
30 Day Avg. Volume94,141
Financial Highlights & Ratios
PEG Ratio0.30
Price to Book (P/B)5.05
Price to Sales (P/S)0.00
P/FCF Ratio-9.15
Enterprise Value/Market Cap-1.99
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit280.44
Enterprise Value/Ebitda5.39
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Improving Cash BurnThe marked reduction in cash burn and materially improved free cash flow over multiple years signals durable cost discipline and operational resizing. This improves runway visibility and reduces near-term refinancing urgency, allowing management to focus on advancing clinical programs rather than emergency capital raises.
Zero Corporate DebtHaving no recorded debt substantially reduces solvency and interest-service risk, preserving financial flexibility to fund R&D or negotiate partnerships. A debt-free balance sheet supports strategic optionality in a capital-intensive clinical-stage biotech environment and cushions against adverse funding cycles.
Specialized Cell And Gene Therapy PipelineA focused pipeline in engineered cell and gene therapies targets high unmet medical need with significant scientific barriers and long-term market potential. This specialized expertise creates a durable competitive position for partnerships, licensing, and value creation if clinical milestones are achieved.
Bears Say
No Product RevenueAbsence of any product revenue means the company remains unproven commercially and entirely reliant on development outcomes. Without commercial cash flows, funding must come from financing or deals, increasing execution risk and making long-term sustainability contingent on successful clinical progress or partner licensing.
Persistent Negative Free Cash FlowContinued negative operating and free cash flow, even as burn narrows, implies ongoing dependence on external capital. Recurring financings dilute existing shareholders, create timing risk around trials, and can constrain strategic choices if access to capital tightens during extended clinical development.
Very Small Operating BaseA materially reduced asset base and a tiny headcount limit internal execution capacity for parallel trials and complex manufacturing tasks. This heightens reliance on external partners/CMOs, slows program scalability, and amplifies operational risk if any single outsourced relationship or program faces setbacks.
Mustang Bio News
MBIO FAQ
What was Mustang Bio Inc’s price range in the past 12 months?
Mustang Bio Inc lowest stock price was $0.53 and its highest was $7.00 in the past 12 months.
What is Mustang Bio Inc’s market cap?
Mustang Bio Inc’s market cap is $5.77M.
When is Mustang Bio Inc’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Mustang Bio Inc’s earnings last quarter?
Currently, no data Available
Is Mustang Bio Inc overvalued?
According to Wall Street analysts Mustang Bio Inc’s price is currently Overvalued.
Does Mustang Bio Inc pay dividends?
Mustang Bio Inc does not currently pay dividends.
What is Mustang Bio Inc’s EPS estimate?
Mustang Bio Inc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Mustang Bio Inc have?
Mustang Bio Inc has 6,732,092 shares outstanding.
What happened to Mustang Bio Inc’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Mustang Bio Inc?
Currently, no hedge funds are holding shares in MBIO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Mustang Bio Inc
Mustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on translating medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. Its pipeline focuses on gene therapy programs for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors. The company develops MB-107 and MB-207, a gene therapy program for X-linked severe combined immunodeficiency, a rare genetic immune system condition in which affected patients do not live beyond infancy without treatment. The company also develops MB-102 CAR T therapies for blastic plasmacytoid dendritic cell neoplasm, acute myeloid leukemia, and myelodysplastic syndrome; MB-106 CAR T cell program for B cell non-hodgkin lymphoma and chronic lymphocytic leukemia; MB-104 CAR T for multiple myeloma and light chain amyloidosis; MB-101 CAR T cell program for glioblastoma; MB-103 CAR T for glioblastoma multiforme (GBM) and metastatic breast cancer to brain; MB-105 CAR T for prostate and pancreatic cancers; and MB-108, a next-generation oncolytic herpes simplex virus. It has license agreements with Nationwide Children's Hospital, CSL Behring; Mayo Clin Mayo Clinic; Leiden University Medical Centre; SIRION Biotech GmbH, and Minaris Regenerative Medicine GmbH. The company was incorporated in 2015 and is headquartered in Worcester, Massachusetts.
Technical Analysis
XTL Biopharmaceuticals Sponsored ADR
―
Lyra Therapeutics
―
Bolt Biotherapeutics
―
Silexion Therapeutics
―
Acurx Pharmaceuticals
―
Ownership Overview
8.35% Insiders
0.97% Mutual Funds
1.35% Other Institutional Investors
88.93% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---